Last deal

$8.5M
Local Amount - EUR 7.8M

Amount

Series A

Stage

08.08.2024

Date

2

all rounds

$13M

Total amount

General

About Company
PL BioScience offers advanced 2D and 3D cell culture solutions based on human Platelet Lysate.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

The company provides cell culture supplements derived from outdated human platelets that are subjected to a freeze-thaw process to induce growth factors release, allowing biotech companies and life sciences groups to meet the growing demand for cell culture media for all phases of research and development with stem cells. PL BioScience offers different safety grades of its products, including Research Grade, GMP Grade, and GMP-Clinical Grade, to meet the needs of its customers. Its mission is to enhance advances in cellular research and therapy with its forward-looking Technology: ELAREM™, a platform that unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth but also enables various applications, covering all needs of cell expansion in academic research, pre-clinical research, and cellular therapy. PL BioScience aims to create a future of cell expansion that is animal suffering-free and benefits the regeneration potential of its platelet-derived products.